<DOC>
	<DOCNO>NCT02814565</DOCNO>
	<brief_summary>The purpose study assess effect cyclobenzaprine hydrochloride ( HCl ) extend release ( CER ) 15 mg daily subject muscle spasm associate acute painful musculoskeletal condition .</brief_summary>
	<brief_title>Cyclobenzaprine HCl Extended Release 15mg Versus Placebo Treatment Cervical and/or Lower Back Pain Due Muscle Spasms Local Origin</brief_title>
	<detailed_description>The drug test study call cyclobenzaprine hydrochloride ( HCl ) extended-release ( CER ) . CER test treat people muscle spasms associate acute painful musculoskeletal condition . This study look medication helpfulness , relief muscle spasm pain , improvement range motion daily living activity . The study enroll approximately 180 patient . Participants randomly assign ( chance , like flip coin ) one two treatment groupsâ€”which remain undisclosed patient study doctor study ( unless urgent medical need ) : - CER 15 mg - Placebo ( dummy inactive pill ) - capsule look like study drug active ingredient . All participant ask take one capsule time day throughout study . All participant ask record rating medication helpfulness , relief local pain , clinical global impression</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Neck Pain</mesh_term>
	<mesh_term>Spasm</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Cyclobenzaprine</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . Signs date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Is experience 14 day cervical low back pain ( assessed participant ) due muscle spasm ( confirmed physician ) associate acute , painful musculoskeletal condition . 4 . Is male female age 18 50 year , inclusive . 5 . Female participant require either 2 year postmenopausal surgically sterile bilateral tubal ligation , hysterectomy , bilateral oophorectomy , , premenopausal , use approve contraceptive method . 6 . Female participant childbearing potential must negative urine human chorionic gonadotropin ( hCG ) test result pregnancy study entry . 7 . After sign informed consent form , participant agrees make change dietary , exercise , smoke habit enter weight loss program his/her participation study . 1 . Has muscular pain secondary acute trauma fracture ( e.g. , due osteoporosis ) . Such condition could rule base medical history , xray , physical examination . 2 . Has receive investigational compound within 30 day prior Screening . 3 . If female , participant pregnant lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period . 4 . Has history drug abuse recent ( within last 12 month ) history excessive alcohol consumption define &gt; 2 drinks/day ( &gt; 90 ml 80 proof alcohol equivalent ) . 5 . Has mild , moderate , severe liver impairment . 6 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 7 . Takes concomitant medication include overthecounter herbal product muscle spasm . If participant take medication , medication discontinue start study . 8 . Takes take within last 14 day medication , : 1. selective serotonin reuptake inhibitor ( SSRIs ) ; 2. serotonin norepinephrine reuptake inhibitor ( SNRIs ) ; 3. tricyclic antidepressant ( TCAs ) ; 4. monoamine oxidase ( MAO ) inhibitor ; 5. tramadol ; 6. bupropion ; 7. meperidine ; 8. verapamil ; 9. nonsteroid antiinflammatory drug ( NSAIDs ) ; 10. topical antiinflammatory medication 9 . Has history clinical manifestation significant medical condition , : 1. hyperthyroidism ; 2. acute recovery phase myocardial infarction ; 3. arrhythmia , heart block conduction disturbance ; 4. congestive heart failure ; 5. angleclosure glaucoma ; 6. urinary retention ; 7. increase intraocular pressure . 10 . Has abnormal physical finding medical condition might place participant risk interfere participant 's ability participate study . 11 . Has know condition disorder might affect absorption study drug . 12 . Has history hypersensitivity allergy cyclobenzaprine and/or tricyclic antidepressant component . 13 . Has history hypersensitivity NSAIDs include salicylate sensitivity . 14 . Has history thrombocytopenia . 15 . Has history gastrointestinal bleeding , cerebrovascular bleed bleeding disorder . 16 . Had active history recurrent peptic ulcer/haemorrhage ( two distinct episode proven ulceration bleeding ) 17 . Has history severe renal impairment 18 . Had major surgery 6 month precede study entry . 19 . Has language barrier problem preclude good communication cooperation . 20 . Has reason believe he/she would able complete evaluation need study . 21 . Has know history positive screen hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody . 22 . Drug abuse anamnesis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>